+データを開く
-基本情報
登録情報 | データベース: PDB / ID: 7mn6 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
タイトル | Structure of the HER2 S310F/HER3/NRG1b Heterodimer Extracellular Domain | ||||||||||||
要素 |
| ||||||||||||
キーワード | SIGNALING PROTEIN / Complex / Receptor Tyrosine Kinase | ||||||||||||
機能・相同性 | 機能・相同性情報 neuregulin binding / positive regulation of cardiac muscle tissue development / cranial nerve development / Schwann cell differentiation / neuregulin receptor activity / negative regulation of secretion / endocardial cushion development / negative regulation of immature T cell proliferation in thymus / ERBB3:ERBB2 complex / ERBB2-ERBB4 signaling pathway ...neuregulin binding / positive regulation of cardiac muscle tissue development / cranial nerve development / Schwann cell differentiation / neuregulin receptor activity / negative regulation of secretion / endocardial cushion development / negative regulation of immature T cell proliferation in thymus / ERBB3:ERBB2 complex / ERBB2-ERBB4 signaling pathway / GRB7 events in ERBB2 signaling / immature T cell proliferation in thymus / RNA polymerase I core binding / semaphorin receptor complex / positive regulation of calcineurin-NFAT signaling cascade / peripheral nervous system development / ErbB-3 class receptor binding / regulation of microtubule-based process / negative regulation of cell adhesion / negative regulation of motor neuron apoptotic process / Sema4D induced cell migration and growth-cone collapse / motor neuron axon guidance / motor neuron apoptotic process / neurotransmitter receptor localization to postsynaptic specialization membrane / PLCG1 events in ERBB2 signaling / ERBB2-EGFR signaling pathway / positive regulation of Rho protein signal transduction / ERBB2 Activates PTK6 Signaling / neuromuscular junction development / positive regulation of transcription by RNA polymerase I / Drug-mediated inhibition of ERBB2 signaling / Resistance of ERBB2 KD mutants to trastuzumab / Resistance of ERBB2 KD mutants to sapitinib / Resistance of ERBB2 KD mutants to tesevatinib / Resistance of ERBB2 KD mutants to neratinib / Resistance of ERBB2 KD mutants to osimertinib / Resistance of ERBB2 KD mutants to afatinib / Resistance of ERBB2 KD mutants to AEE788 / Resistance of ERBB2 KD mutants to lapatinib / Drug resistance in ERBB2 TMD/JMD mutants / enzyme-linked receptor protein signaling pathway / detection of maltose stimulus / ERBB2-ERBB3 signaling pathway / protein tyrosine kinase activator activity / Signaling by ERBB4 / maltose transport complex / growth factor binding / oligodendrocyte differentiation / ERBB2 Regulates Cell Motility / maltose binding / carbohydrate transport / maltose transport / maltodextrin transmembrane transport / semaphorin-plexin signaling pathway / PI3K events in ERBB2 signaling / carbohydrate transmembrane transporter activity / lateral plasma membrane / positive regulation of protein targeting to membrane / ATP-binding cassette (ABC) transporter complex, substrate-binding subunit-containing / regulation of angiogenesis / negative regulation of signal transduction / coreceptor activity / Schwann cell development / cell surface receptor protein tyrosine kinase signaling pathway / extrinsic apoptotic signaling pathway in absence of ligand / Signaling by ERBB2 / cellular response to epidermal growth factor stimulus / TFAP2 (AP-2) family regulates transcription of growth factors and their receptors / myelination / GRB2 events in ERBB2 signaling / transmembrane receptor protein tyrosine kinase activity / phosphatidylinositol 3-kinase/protein kinase B signal transduction / regulation of ERK1 and ERK2 cascade / SHC1 events in ERBB2 signaling / positive regulation of cell adhesion / Downregulation of ERBB2:ERBB3 signaling / Constitutive Signaling by Overexpressed ERBB2 / neurogenesis / ATP-binding cassette (ABC) transporter complex / positive regulation of epithelial cell proliferation / basal plasma membrane / cell chemotaxis / positive regulation of translation / Signaling by ERBB2 TMD/JMD mutants / positive regulation of MAP kinase activity / wound healing / Signaling by ERBB2 ECD mutants / neuromuscular junction / Signaling by ERBB2 KD Mutants / receptor protein-tyrosine kinase / neuron differentiation / cellular response to growth factor stimulus / receptor tyrosine kinase binding / Downregulation of ERBB2 signaling / peptidyl-tyrosine phosphorylation / ruffle membrane / Constitutive Signaling by Aberrant PI3K in Cancer / transmembrane signaling receptor activity / PIP3 activates AKT signaling / myelin sheath 類似検索 - 分子機能 | ||||||||||||
生物種 | Homo sapiens (ヒト) Escherichia coli (大腸菌) | ||||||||||||
手法 | 電子顕微鏡法 / 単粒子再構成法 / クライオ電子顕微鏡法 / 解像度: 3.09 Å | ||||||||||||
データ登録者 | Diwanji, D. / Trenker, R. / Verba, K.A. / Jura, N. | ||||||||||||
資金援助 | 米国, ドイツ, 3件
| ||||||||||||
引用 | ジャーナル: Nature / 年: 2021 タイトル: Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface. 著者: Devan Diwanji / Raphael Trenker / Tarjani M Thaker / Feng Wang / David A Agard / Kliment A Verba / Natalia Jura / 要旨: Human epidermal growth factor receptor 2 (HER2) and HER3 form a potent pro-oncogenic heterocomplex upon binding of growth factor neuregulin-1β (NRG1β). The mechanism by which HER2 and HER3 interact ...Human epidermal growth factor receptor 2 (HER2) and HER3 form a potent pro-oncogenic heterocomplex upon binding of growth factor neuregulin-1β (NRG1β). The mechanism by which HER2 and HER3 interact remains unknown in the absence of any structures of the complex. Here we isolated the NRG1β-bound near full-length HER2-HER3 dimer and, using cryo-electron microscopy, reconstructed the extracellulardomain module, revealing unexpected dynamics at the HER2-HER3 dimerization interface. We show that the dimerization arm of NRG1β-bound HER3 is unresolved because the apo HER2 monomer does not undergo a ligand-induced conformational change needed to establish a HER3 dimerization arm-binding pocket. In a structure of the oncogenic extracellular domain mutant HER2(S310F), we observe a compensatory interaction with the HER3 dimerization arm that stabilizes the dimerization interface. Both HER2-HER3 and HER2(S310F)-HER3 retain the capacity to bind to the HER2-directed therapeutic antibody trastuzumab, but the mutant complex does not bind to pertuzumab. Our structure of the HER2(S310F)-HER3-NRG1β-trastuzumab Fab complex reveals that the receptor dimer undergoes a conformational change to accommodate trastuzumab. Thus, similar to oncogenic mutations, therapeutic agents exploit the intrinsic dynamics of the HER2-HER3 heterodimer. The unique features of a singly liganded HER2-HER3 heterodimer underscore the allosteric sensing of ligand occupancy by the dimerization interface and explain why extracellular domains of HER2 do not homo-associate via a canonical active dimer interface. | ||||||||||||
履歴 |
|
-構造の表示
ムービー |
ムービービューア |
---|---|
構造ビューア | 分子: MolmilJmol/JSmol |
-ダウンロードとリンク
-ダウンロード
PDBx/mmCIF形式 | 7mn6.cif.gz | 278.4 KB | 表示 | PDBx/mmCIF形式 |
---|---|---|---|---|
PDB形式 | pdb7mn6.ent.gz | 214.1 KB | 表示 | PDB形式 |
PDBx/mmJSON形式 | 7mn6.json.gz | ツリー表示 | PDBx/mmJSON形式 | |
その他 | その他のダウンロード |
-検証レポート
文書・要旨 | 7mn6_validation.pdf.gz | 1.5 MB | 表示 | wwPDB検証レポート |
---|---|---|---|---|
文書・詳細版 | 7mn6_full_validation.pdf.gz | 1.5 MB | 表示 | |
XML形式データ | 7mn6_validation.xml.gz | 52.1 KB | 表示 | |
CIF形式データ | 7mn6_validation.cif.gz | 76.7 KB | 表示 | |
アーカイブディレクトリ | https://data.pdbj.org/pub/pdb/validation_reports/mn/7mn6 ftp://data.pdbj.org/pub/pdb/validation_reports/mn/7mn6 | HTTPS FTP |
-関連構造データ
-リンク
-集合体
登録構造単位 |
|
---|---|
1 |
|
-要素
-Receptor tyrosine-protein kinase erbB- ... , 2種, 2分子 AB
#1: タンパク質 | 分子量: 117852.719 Da / 分子数: 1 / 断片: Extracellular Domain / 由来タイプ: 組換発現 / 由来: (組換発現) Homo sapiens (ヒト) / 遺伝子: ERBB3, HER3 / 発現宿主: Homo sapiens (ヒト) / 参照: UniProt: P21860, receptor protein-tyrosine kinase |
---|---|
#2: タンパク質 | 分子量: 160556.562 Da / 分子数: 1 / 断片: Extracellular Domain / Mutation: S310F / 由来タイプ: 組換発現 / 詳細: This mutation is oncogenic 由来: (組換発現) Homo sapiens (ヒト), (組換発現) Escherichia coli (大腸菌) 遺伝子: ERBB2, HER2, MLN19, NEU, NGL, malE, b4034, JW3994 株: K12 / 発現宿主: Homo sapiens (ヒト) 参照: UniProt: P04626, UniProt: P0AEX9, receptor protein-tyrosine kinase |
-タンパク質 , 1種, 1分子 H
#3: タンパク質 | 分子量: 9748.859 Da / 分子数: 1 / 断片: EGF-like Domain / 由来タイプ: 組換発現 / 由来: (組換発現) Homo sapiens (ヒト) / 遺伝子: NRG1, GGF, HGL, HRGA, NDF, SMDF / 発現宿主: Escherichia coli (大腸菌) / 参照: UniProt: Q02297-6 |
---|
-糖 , 3種, 8分子
#4: 多糖 | #5: 多糖 | alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1- ...alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose | #6: 糖 | ChemComp-NAG / |
---|
-詳細
研究の焦点であるリガンドがあるか | N |
---|
-実験情報
-実験
実験 | 手法: 電子顕微鏡法 |
---|---|
EM実験 | 試料の集合状態: PARTICLE / 3次元再構成法: 単粒子再構成法 |
-試料調製
構成要素 |
| ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
分子量 | 実験値: NO | ||||||||||||||||||||||||||||||
由来(天然) |
| ||||||||||||||||||||||||||||||
由来(組換発現) |
| ||||||||||||||||||||||||||||||
緩衝液 | pH: 7.4 | ||||||||||||||||||||||||||||||
試料 | 包埋: NO / シャドウイング: NO / 染色: NO / 凍結: YES | ||||||||||||||||||||||||||||||
急速凍結 | 凍結剤: ETHANE |
-電子顕微鏡撮影
実験機器 | モデル: Titan Krios / 画像提供: FEI Company |
---|---|
顕微鏡 | モデル: FEI TITAN KRIOS |
電子銃 | 電子線源: FIELD EMISSION GUN / 加速電圧: 300 kV / 照射モード: FLOOD BEAM |
電子レンズ | モード: BRIGHT FIELD |
撮影 | 電子線照射量: 67 e/Å2 / フィルム・検出器のモデル: GATAN K3 (6k x 4k) |
-解析
EMソフトウェア |
| ||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CTF補正 | タイプ: PHASE FLIPPING AND AMPLITUDE CORRECTION | ||||||||||||||||||||||||||||||||
3次元再構成 | 解像度: 3.09 Å / 解像度の算出法: FSC 0.143 CUT-OFF / 粒子像の数: 99755 / 対称性のタイプ: POINT | ||||||||||||||||||||||||||||||||
原子モデル構築 |
|